Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-Induced Myotoxicity
This study has been completed.
Sponsor:
University of Oslo School of Pharmacy
Information provided by:
University of Oslo School of Pharmacy
ClinicalTrials.gov Identifier:
NCT00120055
First received: July 7, 2005
Last updated: July 13, 2005
Last verified: June 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.
Condition | Intervention | Phase |
---|---|---|
Myopathy |
Drug: Atorvastatin (Lipitor) |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
Resource links provided by NLM:
MedlinePlus related topics:
Muscle Disorders
Drug Information available for:
Atorvastatin calcium
U.S. FDA Resources
Further study details as provided by University of Oslo School of Pharmacy:
Study Start Date: | February 2005 |
Estimated Study Completion Date: | April 2005 |
A 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in 15 patients with a history of atorvastatin -induced myotoxicity. The possible link to relevant mutations in SLCO1B1, CYP3A5 and MDR1 will be also be investigated
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- above 18 years
- previous history of atorvastatin-associated myotoxicity
Exclusion Criteria:
- current treatment with drugs or herbal remedies with known pharmacokinetic interaction potential with atorvastatin
- previous CK levels above ten times the upper limit of normal range
- pregnancy and persistent muscular complaints after a four week wash-out period of statin treatment
Contacts and Locations
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
ClinicalTrials.gov Identifier: | NCT00120055 History of Changes |
Other Study ID Numbers: | AVALIP04 |
Study First Received: | July 7, 2005 |
Last Updated: | July 13, 2005 |
Health Authority: | Norway: Norwegian Medicines Agency |
Additional relevant MeSH terms:
Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Atorvastatin Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents |
Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Enzyme Inhibitors Lipid Regulating Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 16, 2012